How to Evaluate a Company's R&D Spending

Pharmaceutical giant Eli Lilly spent roughly $9 billion on R&D in a single year — about 25% of its revenue. Apple spent over $30 billion — but that's less than 8% of its revenue. General Motors spent more on R&D than Tesla. Yet none of these comparisons tells you which company is getting the best return on its research investment. R&D spending is one of the most important — and most poorly evaluated — line items on the income statement.

Why R&D Matters for Investors

R&D spending is the seed corn of future competitive advantage. Today's research produces tomorrow's products, patents, and process improvements. A company that underinvests in R&D may deliver higher short-term margins, but it's borrowing from its future competitiveness. A company that invests wisely in R&D is building intangible assets that don't appear on the balance sheet but drive long-term value creation.

Under current accounting rules, nearly all R&D spending is expensed immediately — it reduces reported earnings in the year it's incurred, even though the benefits may not materialize for years or decades. This accounting treatment means that heavy R&D spenders look less profitable than they actually are, because their investments in future products are treated as current-period costs rather than long-term assets.

This creates a systematic undervaluation opportunity. A company spending $2 billion per year on R&D that consistently produces successful products is building an invisible asset — a pipeline of future revenue — that's worth far more than the $2 billion expense suggests. Investors who focus solely on reported earnings miss this embedded value.

Metrics That Matter

R&D as a percentage of revenue is the starting point but not the conclusion. A company spending 15% of revenue on R&D is investing more intensively than one spending 3%, but that doesn't mean it's investing more wisely. Context matters: pharmaceutical companies typically spend 15-25% because drug development is extraordinarily expensive and risky. Software companies spend 15-25% because rapid innovation is essential to competitiveness. Industrial companies spend 3-5% because their innovation cycles are longer and their products are more mature.

R&D yield — the revenue generated per dollar of historical R&D spending — is a more meaningful metric. If a company has spent $10 billion on R&D over the past five years and that spending has produced products generating $5 billion in annual revenue, the yield is meaningful. If the $10 billion produced products generating only $500 million, the R&D program is struggling.

Patent quality and quantity provide a partial window into R&D productivity, though they're imperfect. Companies that generate large numbers of patents in core technology areas are building defensible intellectual property. But patent counts can be gamed — some companies file large numbers of low-value patents to inflate metrics — so the quality and commercial relevance of the patent portfolio matters more than the raw count.

Product pipeline assessment is essential for pharmaceutical and biotechnology companies, where R&D success is binary and transparent. The number of drugs in clinical trials, their stage of development, the size of their addressable markets, and the probability of regulatory approval can be estimated with reasonable accuracy and compared to the R&D spending required to produce them.

Red Flags in R&D Spending

Rising R&D spending with declining revenue growth suggests diminishing returns on research investment. The company is spending more to produce less — a sign that its innovation engine is losing effectiveness or that competition is eroding the value of its innovations.

R&D spending cuts during strategic transitions are a warning. When a company facing competitive disruption reduces R&D to protect near-term margins, it's sacrificing its future to flatter the present. This is particularly dangerous in technology and pharmaceutical companies, where the competitive consequences of reduced R&D take years to manifest but are nearly impossible to reverse.

Acquisitions substituting for organic R&D can indicate a weakening innovation culture. Some companies prefer to acquire innovation rather than develop it internally — buying startups and smaller companies rather than investing in their own research. This can work if the acquisitions are well-executed, but it often signals that the internal R&D function has lost its ability to produce competitive products.

R&D and Moat Durability

For quality investors, R&D spending is a leading indicator of moat durability. A company with a wide moat that continues to invest heavily in research is reinforcing and extending its competitive advantages. A company with a wide moat that's cutting R&D may be harvesting its current advantages without building new ones — a strategy that works for years but eventually erodes the moat from within.

The best companies — the ones with the most durable moats — have R&D programs that consistently produce innovations that strengthen their competitive position. Apple's R&D produces chips that make its devices faster and more efficient. ASML's R&D produces lithography machines that no competitor can match. These companies spend heavily on R&D because the returns justify the investment, and the investment itself is a moat source.